![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H34O8 |
Molar mass | 498.572 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease.[1][2] It reached Phase III clinical trials, but development was discontinued in 1996.[2]
| |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor (ligands) |
| ||||||||||||||||
Enzyme (inhibitors) |
| ||||||||||||||||
Others |
| ||||||||||||||||
|
![]() | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |